‘Innovation procurement for Drug Detection in correctional institutions and prisons’ — DrugDetect

The solution proposed by the Tenderer must comprise one or more innovative components or one or more architectural innovations. The Drug Detect procurement does not include the procurement of research and development (R&D).  In particular, the proposed solution must comprise new or significantly improved components or architecture that have already been (partially) demonstrated on a small scale and may be nearly or already available in small quantities on the market, but which have not been widely adopted yet. Typically, owing to the residual risk or market uncertainty, these innovative components or architecture have not been produced at a large enough scale. This also includes existing solutions that are to be utilised in a new and innovative way.  Whether a component or architectural feature is innovative will be assessed by the Drug Detect consortium according to the following three cumulative minimum requirements: 1. The innovative component or architectural innovation must be related to innovation aspects indicated as important for the given lot. 2. The difference in time between first deployment of the device/solution, which is equipped with such a component or is based on such architectural innovations, and the date, when the given Tender was due for submission, must not exceed 24 months. 3. Finally, the component or architectural innovation in question must not have been used for more than 50 clients. These cumulative minimum requirements will be assessed for each bid submitted. Final Tenders that do not conform to this minimal requirement will be excluded. In Lot 3, the Buyers’ Group is interested in the following innovative features: Speed of scanning Minimal operator interaction Artificial Intelligence to support recognition of suspicious objects/drugs Integration with other relevant functionalities such as air sampling/trace detection etc. Accuracy of detection Improved detection of feet, hair etc.